https://panajotovikj.com/blog/what-are-reasoning-llms/2026-06-03monthly0.8https://panajotovikj.com/blog/fine-tuning-small-models-for-drug-safety/2026-06-03monthly0.8https://panajotovikj.com/blog/on-detecting-ai-writing/2026-06-03monthly0.8https://panajotovikj.com/blog/multi-agent-llm-architectures-for-drug-safety/2026-06-03monthly0.8https://panajotovikj.com/blog/how-llms-handle-and-mishandle-medical-terminology/2026-06-03monthly0.8https://panajotovikj.com/blog/can-llms-detect-negation-reliably-in-safety-narratives/2026-06-03monthly0.8https://panajotovikj.com/blog/drug-safety-lost-in-the-middle/2026-06-03monthly0.8https://panajotovikj.com/blog/stimulated-reporting-weber-effects-and-disproportionality/2026-06-03monthly0.8https://panajotovikj.com/blog/pediatric-pharmacovigilance/2026-06-03monthly0.8https://panajotovikj.com/blog/benchmarking-signal-detection-the-reference-set-problem/2026-06-03monthly0.8https://panajotovikj.com/blog/spontaneous-reporting-systems/2026-06-03monthly0.8https://panajotovikj.com/blog/diabetes-drug-affects-brain/2026-06-03monthly0.8https://panajotovikj.com/blog/artificial-intelligence-and-large-language-models-in-drug-safety/2026-06-03monthly0.8https://panajotovikj.com/blog/why-rag-matters-more-than-model-size-in-pharmacovigilance/2026-06-03monthly0.8https://panajotovikj.com/blog/evaluating-llms-for-pharmacovigilance-beyond-f1/2026-06-03monthly0.8https://panajotovikj.com/blog/when-drug-safety-LLMs-stop-being-demos-and-start-becoming-infrastructure/2026-06-03monthly0.8https://panajotovikj.com/blog/signal-detection-in-pharmacovigilance/2026-06-03monthly0.8https://panajotovikj.com/weekly1.0https://panajotovikj.com/blog/daily0.9https://panajotovikj.com/cv/yearly0.6